Core Viewpoint - Dingtang Health (09886) has experienced a significant stock price increase of nearly 23% following the announcement of a profit warning, indicating an expected reduction in net losses for the mid-2025 period compared to the same period in 2024 [1] Financial Performance - The expected net loss for mid-2025 is projected to narrow by over 40% compared to the net loss of approximately RMB 89.8 million in the same period of 2024 [1] - The adjusted net loss (non-IFRS measure) for mid-2025 is anticipated to decrease by over RMB 20 million compared to the adjusted net loss of approximately RMB 26.4 million for the six months ending June 30, 2024 [1] Operational Developments - Dingtang Health is increasing its investment in technology applications to enhance the capabilities of Dingtang Smart Pharmacy, including the use of smart picking equipment and pilot self-service vending machines in Beijing [1] - The company has established four major smart warehouses in North China, Central China, East China, and South China, creating an efficient and professional smart warehousing and retail service network connected to hundreds of multifunctional smart pharmacies nationwide [1] - The Dingtang smart warehouse's visual central control system is integrated with the Dingtang Xingyuan system, forming a data closed-loop management system that enables inventory monitoring, batch management, and expiration warnings, significantly optimizing inventory turnover and control [1]

Core Viewpoint - Dingdang Health (09886) has experienced a significant stock price increase of nearly 23% following the announcement of a profit warning, indicating an expected reduction in net losses for the mid-2025 period compared to the same period in 2024 [1] Financial Performance - The expected net loss for mid-2025 is projected to narrow by over 40% compared to the net loss of approximately RMB 89.8 million for the same period in 2024 [1] - The adjusted net loss (non-IFRS measure) for mid-2025 is anticipated to decrease by over RMB 20 million compared to the adjusted net loss of approximately RMB 26.4 million for the six months ending June 30, 2024 [1] Operational Developments - Dingdang Health is increasing its investment in technology applications to enhance the capabilities of Dingdang Smart Pharmacy, including the use of smart picking equipment and pilot self-service vending machines in Beijing [1] - The company has established four major smart warehouses in North China, Central China, East China, and South China, creating an efficient and professional smart warehousing and retail service network in conjunction with hundreds of multifunctional smart pharmacies nationwide [1] - The visual central control system of Dingdang Smart Warehouse is integrated with the Dingdang Star Ring system, forming a closed-loop data management system that enables inventory monitoring, batch management, and expiration warnings, significantly optimizing inventory turnover and control [1]

Core Viewpoint - Dingtang Health (09886) has experienced a significant stock price increase of nearly 23% following the announcement of a profit warning, indicating an expected reduction in net losses for the mid-2025 period compared to the same period in 2024 [1] Financial Performance - The expected net loss for mid-2025 is projected to narrow by over 40% compared to a net loss of approximately RMB 89.8 million in the same period of 2024 [1] - The adjusted net loss (non-IFRS) for mid-2025 is anticipated to decrease by over RMB 20 million compared to an adjusted net loss of approximately RMB 26.4 million for the six months ending June 30, 2024 [1] Operational Developments - Dingtang Health is increasing its investment in technology applications to enhance the capabilities of its smart pharmacy, including the use of intelligent picking equipment and pilot self-service vending machines in Beijing [1] - The company has established four major intelligent warehouses in North China, Central China, East China, and South China, creating a professional and efficient smart warehousing and retail service network [1] - The Dingtang intelligent warehouse's visual central control system is integrated with the Dingtang Xingyuan system, forming a closed-loop data management system that optimizes inventory turnover and control, while reducing turnaround time from warehouse to store [1]

Group 1 - The core viewpoint of the article highlights a significant increase in the demand for mosquito repellent products in Guangzhou, Shenzhen, and Foshan, with a search volume growth of 472% compared to the same period last year [1] - The sales of mosquito repellent products have also seen a substantial increase, with a growth of 343% year-on-year [1] - In the last two weeks, the sales of mosquito repellent products have surged by 163% on a month-on-month basis [1]

Core Viewpoint - Dingdang Health (09886.HK) has scheduled a board meeting on August 22, 2025, to review and approve the interim results for the six months ending June 30, 2025, and to consider the payment of an interim dividend, if any [1] Group 1 - The board meeting is set for August 22, 2025 [1] - The meeting will focus on the interim results for the period ending June 30, 2025 [1] - The company will also consider the potential payment of an interim dividend [1]

（股份代號：09886） 董事會會議日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 DINGDANG HEALTH TECHNOLOGY GROUP LTD. 叮噹健康科技集團有限公司 （於開曼群島註冊成立的有限公司） 主 席 楊文龍 香 港，2025年8月12日 截 至 本 公 告 日 期，執 行 董 事 為 楊 文 龍 先 生、徐 寧 先 生、俞 雷 先 生、于 慶 龍 先 生 及 楊 益 斌 先 生，非 執 行 董 事 為 李 楚 衡 女 士，以 及 獨 立 非 執 行 董 事 為 張 守 川 先 生、樊 臻 宏 博 士 及 姜 山 先 生。 叮 噹 健 康 科 技 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 及 合 併 聯 屬 實 體 統 稱 為「本集團」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 謹 訂 於 2025年8月22 ...

Group 1 - InnoCare (02577.HK) has partnered with NVIDIA to promote the large-scale implementation of the 800 VDC power architecture in AI data centers, which is designed for efficient power supply in megawatt-level computing infrastructure [1] - The 800 VDC system offers significant advantages over traditional 54V systems in terms of efficiency, thermal loss, and reliability, enabling a 100-1000 times increase in AI computing power [1] - The company's third-generation GaN devices provide a comprehensive power solution from 800V input to GPU terminals, covering a voltage range from 15V to 1200V [1] Group 2 - China Ruyi (00136.HK) received a strategic investment of HKD 3.9 billion from Wuji Capital to accelerate business expansion and acquisition plans [2] - LEPU Biopharma-B (02157.HK) has authorized T-cell connector technology with an upfront payment of USD 10 million and potential milestone payments of up to USD 850 million [2] - Sinopec Engineering (02386.HK) signed a front-end engineering design (FEED) contract for a large green hydrogen project in Yanbu, Saudi Arabia [2] Group 3 - Geely Automobile (00175.HK) reported total vehicle sales of 237,700 units in July, a year-on-year increase of 58% [3] - Great Wall Motors (02333.HK) achieved approximately 104,372 vehicle sales in July, reflecting a year-on-year growth of 14.34% [3] - NIO-SW (09866.HK) delivered 21,017 vehicles in July [3]

Core Viewpoint - Dingdang Health (09886.HK) expects a reduction in net loss for the mid-2025 period, narrowing over 40% compared to the net loss of approximately RMB 89.8 million for the same period in 2024, primarily due to improved gross margin and reduced general and administrative expenses [1] Financial Performance - The anticipated adjusted net loss (non-IFRS measure) for mid-2025 is expected to narrow by over RMB 20 million compared to the adjusted net loss of approximately RMB 26.4 million for the six months ending June 30, 2024 [1]

Core Viewpoint - Dingdang Health (09886) expects a reduction of over 40% in net loss for the mid-2025 period compared to a net loss of approximately RMB 89.8 million for the same period in 2024 [1] Financial Performance - The improvement in net loss is primarily attributed to an increase in gross profit due to higher gross margins and a reduction in general and administrative expenses for the mid-2025 period [1] - The adjusted net loss (non-IFRS measure) for the mid-2025 period is expected to decrease by over RMB 20 million compared to an adjusted net loss of approximately RMB 26.4 million for the six months ending June 30, 2024 [1]

格隆汇8月1日丨叮当健康(09886.HK)公告，2025年中期净亏损预期较2024年同期约人民币8980万元净亏 损收窄逾40%。此改善主要归因于毛利率提升所致毛利增加及2025年中期的一般及行政开支减少。2025 年中期经调整净亏损注(非国际财务报告准则计量)预期较截至2024年6月30日止6个月约人民币2640万元 经调整净亏损收窄逾人民币2000万元。 ...